Wednesday 30 th March

GP VTS

Topics covered

 What to consider with contraception

 Pills

 IUD/IUS

 Implants and injection

 Special circumstances

 QOF

 Case studies

Not covering

 Surgical methods - no funding

 Natural methods

 Gillick (in too much detail)

 Infertility

General intro

 Common consultation

 Increased choice

 Benefits and risks

 Unwanted pregnancy

Initial consultation

 Personal preference

 Lifestyle

 Medical history

 Family history

 Risk of STI

Before starting

 Confirm not pregnant

 Previous methods

 Current medical problems

 BP

 Migraine?

 Smoker?

 Family history of cancers

COCP

 Vary by oestrogen content

 Vary by progesterone type

 21 pills then break

Risk greater than benefit

 Aged 35y + smoker

 >50y

 HTN

 IHD/CVA/PVD

 DM

 VTE

 Focal migraine

Risk greater than benefit

 Female malignancy

 Hormonal problems in pregnancy

 Breast feeding

 Acute hepatitis

 Porphyria

Starter pills

 Microgynon 30

 Ovranette

 150mcg - levonorgesterol (progesterone)

 30mcg – ethinylestradiol (oestrogen)

 £2.99

 £2.29

Progesterone side effects

 Acne

 Headache

 Depression

 Weight gain

 Breast symptoms

 Decreased libido

Alternate options

 Desogesterel – Marvelon

 Gestodene – Femodene

 Norgestimate – Cilest

 Drospirenone - Yasmin

 £6.70

 £7.18

 £11.94

 £14.70

Alternate options

 Cyproterone acetate – Dianette

 £3.70

 Not licensed for contraception alone

 Used in treatment of acne

Oestrogen side effects

 Breast tenderness

 Nausea

 Weight gain

 Bloating

 Loestrin 20 – 20mcg ethinylestradiol

 £2.70

Breakthrough bleeding

 First few months

 Exclude other cause

 Compliance

Interactions

 New advice on antibiotics

 Enzyme inducers

 Affect all hormonal contraception

Missed COC pills

 Current advice

 Take ASAP

 2 or less

 3 or more

POP

 Older women

 Smokers

 VTE history

 HTN, DM, Migraine

 Breastfeeding <6m post-partum

Types

 Cerazette- desogesterel - £8.85

 Micronor/Noriday – norethisterone - £2.00

 Femulen – etynodiol - £3.31

 Norgeston – levonorgesterel - £0.98

Starting

 Start on day 1 of cycle

 Take every day – no breaks

 Missed pill

 D+V

Side effects

 Higher failure rate

 Irregular bleeding

 Risk of ectopic

In summary…

 LARC 23% of primary methods of contraception

 LARC methods

 intrauterine devices [IUDs]

 the intrauterine system [IUS] injectable contraceptives

 implants

 all LARCs more cost effective than the COCP even at

1 year of use

 IUDs, the IUS and implants are more cost effective than the injectable contraceptives (DMPA)

Who can use LARCs?

All LARC methods are suitable for:

 nulliparous women

 breastfeeding

 women who have had an abortion

 BMI > 30

 women with HIV – encourage safer sex

 women with diabetes

 women with migraine with or without aura – all progestogen-only methods may be used

 women with contraindication to oestrogen

Important points to discuss:

 contraceptive efficacy

 duration of use

 risks and possible side effects

 non-contraceptive benefits

 initiation and removal/discontinuation

 when to seek help while using the method.

Risks and side effects

Copper IUDs IUS (Mirena) Progestogen-only injections

Unacceptable vaginal bleeding/pain

Ectopic pregnancy

1/20 (lower than without contraception)

Unacceptable vaginal bleeding/pain

Ectopic pregnancy

1/20

Altered bleeding pattern eg. persistent

Small loss in bone mineral density, largely recovered when stopped.

Implants

Irregular bleeding

Acne

PID <1% low risk women

PID <1% Weight gain – up to 2-3kg over a year

Uterine perforation

<1/1000

Uterine perforation

<1/1000

No evidence of effect on depression, acne or headaches

No evidence of effect on weight, mood, libido, headaches, BMD

Mood/libido change

No weight gain

Mood/libido change, acne

No weight gain

Benefits – non contraceptive

 Progestogen-only implants/DMPA may improve dysmenorrhoea and the symptoms of endometriosis.

 Up to 20% of women using a progestogenonly implant will be amenorrhoeic

 A RTC found a significant reduction in dysmenorrhoea and menorrhagia with the

LNG-IUS (Mirena) when compared to a Cu-

IUD.

Implanon/Nexplanon

Implants - update

 Nexplanon® is a progestogen-only subdermal implant ( non palpable ) - now replaced Implanon®.

 Nexplanon and Implanon are bioequivalent (i.e. they both contain 68 mg etonogestrel and they have the same release rate and 3-year duration of action).

 Nexplanon is radio-opaque and has a different application device and insertion technique.

Implants

When fitting:

Check the woman is not pregnant!

Nexplanon may be inserted:

 at any time

(but use barrier methods for first 7 days if the woman is amenorrhoeic or it is more than 5 days since menstrual bleeding started)

Implants

 Prevention of ovulation.

 3 years

 No delay

 20% of users - no bleeding

 50% will have infrequent, frequent or prolonged bleeding

 Bleeding patterns are likely to remain irregular.

 Not recommended for women taking enzymeinducing drugs eg. Anti-epileptics, St.Johns Wort.

 Useful if high BMI

Copper devices or Mirena coil.

Before inserting an IUD or IUS:

 Test for:

 Chlamydia trachomatis in women at risk of

STIs

 Neisseria gonorrhoeae in women at risk of

STIs in areas where it is prevalent

 For woman at increased risk of STIs, give prophylactic antibiotics before inserting an

IUD or IUS if testing has not been completed.

 Like the implant - an IUD or IUS may be inserted:

 at any time

 If the woman has epilepsy, seizure risk may be increased at the time of fitting an IUD or

IUS.

 Women with a history of venous thromboembolism (VTE) may use the IUS.

 Pelvic infection risk - 20 days following insertion

 risk same as non-IUD-using population thereafter

 Irregular bleeding common in the first 6 months after insertion of the LNG-IUS but by 1 year amenorrhoea or light bleeding is usual.

IUDs

 Previous endocarditis

 Prosthetic heart valve

 require intravenous antibiotic prophylaxis

 Copper is toxic to ovum and sperm inhibiting fertilisation.

 In addition, the endometrial inflammatory reaction has an antiimplantation effect and alterations in the copper content of cervical mucus inhibit sperm penetration.

IUDs

 A Cu-IUD inserted when a woman >40 years can be retained until the menopause is confirmed.

 >50yrs - 1 year after the last menstrual period

 <50yrs - 2 years

 Copper IUDs - 5-10 years

IUS - Mirena

 Prevents implantation.

 Effects on cervical mucus reduce sperm penetration.

 Inserted >45 years and amenorrhoeic - may retain the LNG-IUS until the menopause.

 Randomised trials show that the LNG-IUS provides effective contraception for up to 7 years – licensed for 5 years .

After fitting:

 At first follow-up visit (after the first menses, or 3–6 weeks after insertion)

 exclude infection, perforation or expulsion.

 IUD only: For heavier and/or prolonged bleeding associated with use of an IUD:

 – treat with NSAIDs and tranexamic acid

 – or suggest changing to the IUS if the woman finds bleeding unacceptable.

Depo Provera

Injectable contraceptives

Depo Provera or Noristerat (short term use)

Inhibits ovulation.

Check not pregnant!

Can give:

 – up to 5 th day of the menstrual cycle without the need for additional contraceptives

 – or use barrier contraception 7 days

 Every 12 weeks

 Deep intramuscular injection

 into the gluteal or deltoid muscle or the lateral thigh

 Delay up to 1 year in the return of fertility BUT

 …no evidence of reduced fertility long term

 Amenorrhoea (14.4%)

 Infrequent bleeding (24.2%)

 Spotting (27.9%)

 Prolonged bleeding (33.5%) were all reported

 Small loss of BMD, which is usually recovered after discontinuation.

 Women should be advised that there is no available evidence on the effect of DMPA on longterm fracture risk.

 Use may continue to age 50 years.

Managing irregular bleeding

 Can try:

 3 cycles of 20-30mcg COC, taken cyclically

– can be repeated

 If COC contraindicated: mefenamic acid

500mg BD until bleeding settles…

 Cerazette 1 tab daily for approx. 3 months

Managing problems with Depo

Provera

 Repeat injections may be given up to 2 weeks late.

 DMPA use >2 years, review and discuss the balance of benefits and risks again eg. BMD

 No evidence of congenital malformation to the fetus if pregnancy occurs during DMPA use.

 Good choice if on enzyme-inducing drugs

Follow-up required acc. to NICE

Routine follow-up

IUD/IUS

 At 3–6 weeks

 Return if problems or time for removal.

Injectable contraceptives

 Every 12 weeks; every 8 weeks for NET-EN

Implants

 No routine follow-up

Under 16s and post-partum

Fraser Guidelines and Gillick Competence

Under 16s and providing contraception

 Be aware of the law

 Duty of care and a duty of confidentiality to all patients, including under 16s.

 > 25% of young people are sexually active

<16 years.

 Least likely to use contraception.

 Confidentiality

 If considering any disclosure of information

- weigh up a right to privacy against:

 current or likely harm

 what any such disclosure is intended to achieve

 potential benefits to the young person’s well-being.

 Except in the most exceptional of circumstances consult the young person and offer to support a voluntary disclosure.

The Fraser Guidelines:

 the young person understands the health professional’s advice;

 cannot persuade the young person to inform his or her parents or allow the doctor to inform the parents that he or she is seeking contraceptive advice;

 the young person is very likely to begin or continue having intercourse with or without contraceptive treatment;

 unless he or she receives contraceptive advice or treatment, the young person’s physical or mental health or both are likely to suffer;

 the young person’s best interests require the health professional to give contraceptive advice, treatment or both without parental consent .

The Sexual Offences Act 2003

The Act states that, a person is not guilty of aiding, abetting or counselling a sexual offence against a child where they are acting for the purpose of:

 protecting a child from pregnancy or STIs

 protecting the physical safety of a child,

 promoting a child’s emotional well-being by the giving of advice.

Choices for women post-partum, including breastfeeding

 IUD – copper: from 4 weeks after childbirth

 IUS - Mirena: from 4 weeks after childbirth

 DMPA injection: any time after childbirth, if

>21 days need additional.

 Implants - Nexplanon: any time after childbirth; if >21 days postpartum need additional

Abortion/miscarriage

 Progestogen-only injectable contraception or implant is appropriate:

 after surgical abortion

 (second part of) medical abortion

 miscarriage.

 If DMPA or Nexplanon within 5 days

 Ideally insert IUD or IUS within the first 48 hours or delay until 4 weeks postpartum.

Emergency contraception

 Less than 72 hours – levenorgesterol - 1.5mg

 Between 72h and 120h – EllaOne

 Most effective is Copper IUD

Emergency contraception

 Advise to return if abdominal pain or next period overdue

 Advice on STI

 Plan contraceptive follow up

TOP - practicalities

 Less than 24w

 Reasons

 Medical and surgical

 Marie Stopes centres

 http://www.mariestopes.org.uk

QOF

 LARC – offered and coded

 Chlamydia testing – people under 25

Case study 1

 17y

 Only current partner

 BMI 22

 Non-smoker

 Wants contraception

Case study 1

 Comes back 3m later

 Spots over face, some on back

Case study 2

 42y

 Finished family

 Wants something long term

Case study 3

 24y

 New baby

 Unplanned pregnancy

Case study 4

 37y

 Heavy smoker

 BMI 42

 Bed bound

 Diabetic

 Previous DVT

 BP 172/104

Resources

 Faculty of Family Planning

 Oxford handbook of General Practice

 BNF

 Marie Stopes

 Monkgate Clinic